FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)

PMA: P010053 · Decision Jul 26, 2002
Classifications
1
FEI Numbers
27
Registration Numbers
27

Basic Information

Device Name
Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
Trade Name
IMMULITE 2000 XPI ANTI-HBC IMG
PMA Number
P010053
Device Class
FDA Class 3
Product Code
LOM
Generic Name
Test, hepatitis b (b core, be antigen, be antibody, b core igm)
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
July 26, 2002
Date Received
August 31, 2001
Expedited Review
N
Docket Number
03M-0272

Advisory Committee Statement

APPROVAL FOR THE IMMULITE ANTI-HBC IGM AND IMMULITE 2000 ANTI-HBC IGM. THESE DEVICES ARE INDICATED FOR: IMMULITE. ANTI-HBC IGM: IMMULITE ANTI-HBC IGM IS A SOLID-PHASE CHEMILUMINESCENT ENZYME IMMUNOASSAY DESIGNED FOR USE WITH THE IMMULITE AUTOMATED IMMUNOASSAY ANALYZER FOR THE QUALITATIVE MEASUREMENT OF IGM ANTIBODY TO HEPATITIS B CORE ANTIGEN (ANTI-HBC IGM) IN HUMAN SERUM AND PLASMA (EDTA, HEPARINIZED OR CITRATE). IT IS INTENDED FOR IN VITRO DIAGNOSTIC USE FOR THE LABORATORY DIAGNOSIS OF ACUTE OR RECENT (USUALLY WITHIN 6 MONTHS) HEPATITIS B VIRAL INFECTION. IMMULITE. 2000 ANTI-HBC IGM: IMMULITE 2000 ANTI-HBC IGM IS A SOLID-PHASE CHEMILUMINESCENT ENZYME IMMUNOASSAY DESIGNED FOR USE WITH THE IMMULITE 2000 AUTOMATED IMMUNOASSAY ANALYZER FOR THE QUALITATIVE MEASUREMENT IF IGM ANTIBODY TO HEPATITIS B CORE ANTIGEN (ANTI-HBC IGM) IN HUMAN SERUM AND PLASMA (EDTA, HEPARINIZED OR CITRATE). IT IS INTENDED FOR IN VITRO DIAGNOSTIC USE FOR THE LABORATORY DIAGNOSIS OF ACUTE OR RECENT (USUALLY WITHIN 6 MONTHS) HEPATITIS B VIRAL INFECTION.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LOM Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)